AzTrials
AzTrials

CHF - Congestive Heart FailureADHERE-HFNCT07831538

Digital Outreach for Heart Failure Adherence

A study testing Digital Outreach in people with CHF - Congestive Heart Failure, run by Kaiser Permanente at 1 site in United States.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of the ADHERE-HF study is to evaluate whether care-embedded, operationally delivered digital outreach improves medication refill, adherence, and clinical outcomes among adults with heart failure who are overdue for a refill of an eligible guideline-directed medical therapy (GDMT) medication. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
CHF - Congestive Heart Failure
What is being tested?
Digital Outreach
Could I receive a placebo?
No, everyone receives an active treatment
How many people
13,714 participants
Where
1 siteUnited States
Study dates
21 Sep 2026to Mar 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age ≥18 years
  • Active KPNC membership
  • Heart failure diagnosis documented at least 6 months before the index date, with a documented EF
  • Prescribed at least one eligible GDMT medication for ≥6 months:
  • HFpEF (EF≥50%): ARNI (sacubitril/valsartan); MRA; SGLT2i
  • HFrEF or HFmrEF (EF <50%): ARNI (sacubitril/valsartan), ACEi, or ARB; Beta-blocker (bisoprolol, carvedilol, or sustained-release metoprolol succinate); MRA; SGLT2i
  • At least one unfilled refill for an eligible GDMT medication that is 7-13 days overdue at index

Who cannot join

  • Documented allergy or intolerance to all eligible GDMT medications for which the patient is overdue
  • Receiving hospice or comfort-focused care
  • Skilled nursing facility stay within prior 12 months
  • No valid telephone number on file through which the patient could be reached by text message or automated telephone call
  • Opted out of receiving pharmacy medication adherence outreach from Kaiser Permanente
  • Other conditions that prevent outreach

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

United States1 site
  • Kaiser Permanente Division of Research

    Pleasanton, California, 94588

Other trials in United States

About this study

Official title: Adherence Through Digital Health: Evaluating Randomized Engagement in Heart Failure

The goal of the ADHERE-HF study is to evaluate whether care-embedded, operationally delivered digital outreach improves medication refill, adherence, and clinical outcomes among adults with heart failure who are overdue for a refill of an eligible guideline-directed medical therapy (GDMT) medication.

The main question it aims to answer is: Does digital outreach using interactive text messages or automated telephone calls increase short-term refill of overdue heart failure medications compared with usual care?

The study will evaluate the effectiveness of a digital outreach strategy delivered through existing health system communication channels. Members who have opted in to pharmacy text messaging will receive interactive text messages, while those who have not opted in will receive an interactive automated telephone call. The comparison group will receive usual care with no additional outreach.

Read the detailed description

Heart failure is a common chronic condition associated with hospitalization, impaired quality of life, and premature death. Guideline-directed medical therapy (GDMT) can reduce the risk of cardiovascular death and worsening heart failure, but patients must continue to refill and take these medications to receive their full benefit. Medication nonadherence remains common and contributes to a gap between the benefits observed in clinical trials and those achieved in routine care. The ADHERE-HF study is a pragmatic, prospective, open-label, individual-level randomized clinical trial designed to evaluate whether digital outreach improves refill of overdue GDMT medications among adults with heart failure. The study will compare a text-first digital outreach strategy with usual care and will be conducted through existing health system pharmacy operations.

Eligible members will be randomized in a 1:1 ratio to operationally conducted digital outreach or usual care. Randomization will be stratified by ejection fraction category and by whether the member has opted in to pharmacy text outreach at the time of randomization. Members assigned to digital outreach who have opted in to pharmacy text messaging will receive interactive two-way text messages. These messages notify members that they may be due for a medication refill and provide options to request mail-order delivery or pharmacy pickup. Responses indicating medication, cost, dosing, or other concerns may be referred to pharmacy staff for follow-up. Members assigned to digital outreach who have not opted in to pharmacy text messaging will receive an interactive automated telephone call. The call allows members to select among refill options using the telephone keypad. Members may request refill at their usual pharmacy, use or establish mail-order delivery, or transfer to a pharmacy representative for assistance. Members assigned to usual care will receive no additional outreach. All members will continue to receive routine pharmacy refill communications and other standard health system services. Members will remain assigned to their randomized strategy for 12 months. If any eligible GDMT medication becomes overdue during follow-up, members in the digital outreach group may receive additional outreach. Outreach modality will be based on each member's pharmacy text opt-in status at the time of each contact.

The primary outcome is refill, within 14 days of the outreach date, of at least one GDMT medication that was overdue at randomization. Secondary outcomes include refill within 28 days, the proportion of overdue medications refilled, time to first refill, mail-order fulfillment, medication adherence and persistence at 6 and 12 months, heart failure hospitalization, and all-cause mortality. All outcomes will be obtained from routinely collected, operationally available pharmacy dispensing, electronic health record, administrative, and digital communication data.

The study has no study-specific visits or any direct contact by the study team. This study is designed to generate care-embedded, actionable evidence within a learning health system by determining whether scalable digital outreach improves refill and adherence to guideline-directed heart failure medications and whether the strategy should be implemented more broadly.

Being tested
Digital Outreach
Keywords
Heart failure, Heart failure management, Guideline-directed medical therapy, GDMT, Medication adherence, Medication nonadherence, Medication refill, Digital outreach, Patient outreach, Text messaging, SMS, Automated telephone calls, Interactive voice response, Pharmacy outreach, Pragmatic randomized trial, Learning health system
Medical subject headings
Heart Failure, Medication Adherence

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Digital OutreachBehavioural

    Participants assigned to this arm will receive digital outreach encouraging refill of overdue guideline-directed medical therapy (GDMT) medications for heart failure. Participants who have opted in to pharmacy text messaging at the time of outreach will receive interactive text messages. Participants who have not opted in to pharmacy text messaging will receive an interactive automated telephone call. Participants may receive additional outreach during the 12-month intervention period if another eligible GDMT medication becomes overdue.

Study groups in NCT07831538
Study groupRoleWhat they receive
Digital OutreachExperimentalParticipants will receive interactive text messages or automated phone calls encouraging refill of overdue heart failure medications.
Receives: Behavioral: Digital Outreach
Usual CareNo interventionParticipants in this arm will receive usual care with no proactive outreach during the study period.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Refill of at least one overdue GDMT medication (within 14 days)

    Proportion of participants who refill at least one guideline-directed medical therapy (GDMT) medication for which they were overdue at randomization (index) based on pharmacy dispensing records.

    Measured: Within 14 days after outreach

Secondary outcomes (11)
  1. Composite of heart failure hospitalization or all-cause death

    Time to first occurrence of heart failure hospitalization or death from any cause.

    Measured: Up to 12 months after randomization

  2. Time to first refill of an overdue GDMT medication

    Time from outreach to refill of any GDMT medication for which the participant was overdue at randomization, measured using pharmacy dispensing records. Participants who do not refill will be censored at disenrollment, death, or 28 days after outreach.

    Measured: Up to 28 days after outreach

  3. Refill of at least one overdue GDMT medication (within 28 days)

    Proportion of participants who refill at least one GDMT medication for which they were overdue at randomization, based on pharmacy dispensing records.

    Measured: Within 28 days after outreach

  4. Proportion of overdue GDMT medications refilled (within 14 days)

    For each participant, the proportion of GDMT medications overdue at randomization that are refilled, determined from pharmacy dispensing records.

    Measured: Within 14 days after outreach

  5. Proportion of overdue GDMT medications refilled (within 28 days)

    For each participant, the proportion of GDMT medications overdue at randomization that are refilled, determined from pharmacy dispensing records.

    Measured: Within 28 days after outreach

  6. Heart failure hospitalization

    Time to first heart failure hospitalization.

    Measured: Up to 12 months after randomization

  7. All-cause death

    Time to death from any cause

    Measured: Up to 12 months after randomization

  8. Recurrent heart failure hospitalizations

    Total number of heart failure hospitalizations occurring during follow-up.

    Measured: Up to 12 months after randomization

  9. Mail-order fulfillment

    Proportion of participants who receive a mail-order dispense for at least one GDMT medication that was overdue at randomization.

    Measured: Within 14 days after outreach

  10. GDMT adherence (proportion of days covered)

    Adherence to GDMT measured as proportion of days covered (PDC). PDC will be calculated separately by GDMT class and overall across prescribed classes.

    Measured: At 6 months and 12 months after randomization

  11. GDMT persistence

    Persistence with GDMT therapy, defined as time to the first gap in medication supply exceeding 60 days. Persistence will be evaluated separately by GDMT class prescribed.

    Measured: At 6 months and 12 months after randomization

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Sep 2026
  2. Study start21 Sep 2026 (estimated)
  3. Primary completionMar 2027 (estimated)
  4. Study completionMar 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
13,714 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07831538
Sponsor's protocol ID
ADHERE-HF
Acronym
ADHERE-HF
Status last verified
Aug 2026
First submitted
13 Sep 2026
Last updated
1 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Digital Outreach in people with CHF - Congestive Heart Failure, run by Kaiser Permanente at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 1 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Refill of at least one overdue GDMT medication (within 14 days) (time frame: Within 14 days after outreach). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in